{"entity":{"id":"catherine-wu","kind":"person","name":"Catherine J. Wu","aka":[],"tldr":"Led the first personalised neoantigen peptide vaccine trial in melanoma and mapped how CLL evolves under treatment.","summary":"Catherine Wu led the 2017 Nature trial of NeoVax, a personalised neoantigen peptide vaccine that induced durable T-cell responses in melanoma patients, published alongside Şahin's mRNA work as the founding evidence for individualised cancer vaccines. Her laboratory also defined the clonal evolution of chronic lymphocytic leukaemia and its driver mutations. She directs transplantation and cellular therapies at Dana-Farber.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wu%20CJ%5BAuthor%5D%20neoantigen%20vaccine"}],"tags":["vaccine","neoantigen","genomics"],"related":[],"cancers":["melanoma","cll","glioblastoma"],"sections":[],"technologies":["neoantigen-mrna-vaccine","wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber","broad-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Division of Stem Cell Transplantation and Cellular Therapies, Dana-Farber Cancer Institute; Professor, Harvard Medical School","institutionId":"dana-farber","specialisms":["Neoantigen vaccines","Cancer genomics","CLL evolution","Tumour immunology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wu%20CJ%5BAuthor%5D%20neoantigen%20vaccine"}],"papers":[{"title":"An immunogenic personal neoantigen vaccine for patients with melanoma","journal":"Nature","year":2017,"doi":"10.1038/nature22991"},{"title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","journal":"Cell","year":2013,"doi":"10.1016/j.cell.2013.01.019"}]},"route":"/people/catherine-wu/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"institution":[{"id":"broad-institute","kind":"institution","name":"Broad Institute of MIT and Harvard","route":"/institutions/broad-institute/"},{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"}]}}